Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRML
CUSIPN/A
Phone512-519-0400
Debt
Debt-to-Equity Ratio1.16
Current Ratio1.60
Quick Ratio1.56
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.12 million
Price / Sales14.23
Cash FlowN/A
Price / CashN/A
Book Value$0.06 per share
Price / Book9.83
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-10,490,000.00
Net Margins-398.14%
Return on Equity-323.12%
Return on Assets-150.84%
Miscellaneous
Employees40
Outstanding Shares75,270,000
Market Cap$41.39 million
Vermillion (NASDAQ:VRML) Frequently Asked Questions
What is Vermillion's stock symbol?
Vermillion trades on the NASDAQ under the ticker symbol "VRML."
How were Vermillion's earnings last quarter?
Vermillion, Inc. (NASDAQ:VRML) announced its quarterly earnings results on Thursday, August, 9th. The company reported ($0.04) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.04). The business earned $0.71 million during the quarter. Vermillion had a negative net margin of 398.14% and a negative return on equity of 323.12%. View Vermillion's Earnings History.
When is Vermillion's next earnings date?
What price target have analysts set for VRML?
1 brokers have issued 1 year price targets for Vermillion's shares. Their predictions range from $2.25 to $2.25. On average, they expect Vermillion's stock price to reach $2.25 in the next year. This suggests a possible upside of 281.4% from the stock's current price. View Analyst Price Targets for Vermillion.
What is the consensus analysts' recommendation for Vermillion?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vermillion in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vermillion.
Who are some of Vermillion's key competitors?
Some companies that are related to Vermillion include Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Akers Biosciences (AKER), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Vermillion's key executives?
Vermillion's management team includes the folowing people:
- Ms. Valerie Barber Palmieri, CEO, Pres & Director (Age 57)
- Mr. Robert Harry Beechey CPA, Chief Financial Officer (Age 55)
- Mr. Chris Goulart, Sr. VP of Commercial Operations
- Dr. Jean-François Formela, Exec. Officer (Age 61)
- Mr. Patrick Carpenter, Gen. Mang. of ASPiRA LABS
Has Vermillion been receiving favorable news coverage?
Media headlines about VRML stock have been trending somewhat negative on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vermillion earned a news and rumor sentiment score of -0.11 on Accern's scale. They also gave headlines about the company an impact score of 47.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Vermillion.
Who are Vermillion's major shareholders?
Vermillion's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (4.85%), Birchview Capital LP (3.19%), Manatuck Hill Partners LLC (0.50%) and Lincoln National Corp (0.18%). Company insiders that own Vermillion stock include Eric Schoen, Jack W Schuler, Larry N Feinberg, Robert Harry Beechey, Valerie Barber Palmieri and Veronica Gh Jordan. View Institutional Ownership Trends for Vermillion.
Which major investors are selling Vermillion stock?
Which major investors are buying Vermillion stock?
VRML stock was bought by a variety of institutional investors in the last quarter, including Manatuck Hill Partners LLC and Lincoln National Corp. Company insiders that have bought Vermillion stock in the last two years include Eric Schoen, Jack W Schuler, Larry N Feinberg, Robert Harry Beechey, Valerie Barber Palmieri and Veronica Gh Jordan. View Insider Buying and Selling for Vermillion.
How do I buy shares of Vermillion?
Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vermillion's stock price today?
One share of VRML stock can currently be purchased for approximately $0.59.
How big of a company is Vermillion?
Vermillion has a market capitalization of $41.39 million and generates $3.12 million in revenue each year. Vermillion employs 40 workers across the globe.
How can I contact Vermillion?
Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]
MarketBeat Community Rating for Vermillion (NASDAQ VRML)
MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe VRML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days.
